A detailed history of Ellis Investment Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Ellis Investment Partners, LLC holds 7,296 shares of ABBV stock, worth $1.34 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
7,296
Previous 8,432 13.47%
Holding current value
$1.34 Million
Previous $1.45 Million 0.41%
% of portfolio
0.29%
Previous 0.31%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$163.84 - $199.33 $186,122 - $226,438
-1,136 Reduced 13.47%
7,296 $1.44 Million
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $35,137 - $41,032
227 Added 2.77%
8,432 $1.45 Million
Q1 2024

Apr 15, 2024

SELL
$159.82 - $182.1 $225,506 - $256,943
-1,411 Reduced 14.67%
8,205 $1.49 Million
Q4 2023

Jan 29, 2024

SELL
$137.6 - $154.97 $18,300 - $20,611
-133 Reduced 1.36%
9,616 $1.49 Million
Q3 2023

Nov 01, 2023

SELL
$133.59 - $154.65 $352,009 - $407,502
-2,635 Reduced 21.28%
9,749 $1.45 Million
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $283,041 - $352,226
-2,136 Reduced 14.71%
12,384 $1.67 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $204,767 - $235,820
-1,416 Reduced 8.89%
14,520 $2.31 Million
Q4 2022

Jan 31, 2023

SELL
$138.31 - $165.87 $165,557 - $198,546
-1,197 Reduced 6.99%
15,936 $2.58 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $806,333 - $924,811
-6,008 Reduced 25.96%
17,133 $2.3 Million
Q2 2022

Aug 01, 2022

SELL
$137.62 - $174.96 $865,492 - $1.1 Million
-6,289 Reduced 21.37%
23,141 $3.54 Million
Q1 2022

May 03, 2022

SELL
$131.98 - $163.75 $944,844 - $1.17 Million
-7,159 Reduced 19.57%
29,430 $4.77 Million
Q4 2021

Feb 01, 2022

BUY
$107.43 - $135.93 $29,543 - $37,380
275 Added 0.76%
36,589 $4.95 Million
Q3 2021

Oct 21, 2021

BUY
$106.4 - $120.78 $1,170 - $1,328
11 Added 0.03%
36,314 $3.92 Million
Q2 2021

Jul 26, 2021

BUY
$105.21 - $117.21 $24,619 - $27,427
234 Added 0.65%
36,303 $4.09 Million
Q1 2021

May 03, 2021

SELL
$102.3 - $112.62 $1,943 - $2,139
-19 Reduced 0.05%
36,069 $3.9 Million
Q4 2020

Jan 20, 2021

BUY
$80.49 - $108.67 $643 - $869
8 Added 0.02%
36,088 $3.87 Million
Q3 2020

Oct 19, 2020

BUY
$85.91 - $100.83 $72,851 - $85,503
848 Added 2.41%
36,080 $3.16 Million
Q2 2020

Jul 13, 2020

BUY
$73.37 - $98.18 $188,487 - $252,224
2,569 Added 7.87%
35,232 $3.49 Million
Q1 2020

Apr 17, 2020

SELL
$64.5 - $97.79 $5,289 - $8,018
-82 Reduced 0.25%
32,663 $2.4 Million
Q4 2019

Jan 07, 2020

SELL
$72.13 - $90.25 $48,471 - $60,648
-672 Reduced 2.01%
32,745 $2.93 Million
Q3 2019

Oct 09, 2019

BUY
$62.98 - $75.72 $43,708 - $52,549
694 Added 2.12%
33,417 $2.45 Million
Q2 2019

Jul 24, 2019

SELL
$65.7 - $83.98 $48,355 - $61,809
-736 Reduced 2.2%
32,723 $2.4 Million
Q1 2019

Apr 25, 2019

SELL
$77.14 - $90.79 $212 Million - $249 Million
-2,743,619 Reduced 98.8%
33,459 $2.7 Million
Q1 2019

Apr 24, 2019

BUY
$77.14 - $90.79 $214 Million - $252 Million
2,777,078 New
2,777,078 $2.78 Million
Q1 2019

Apr 22, 2019

SELL
$77.14 - $90.79 $2.65 Million - $3.11 Million
-34,295 Closed
0 $0
Q4 2018

Jan 29, 2019

BUY
$77.85 - $96.01 $2.67 Million - $3.29 Million
34,295 New
34,295 $3.16 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Ellis Investment Partners, LLC Portfolio

Follow Ellis Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ellis Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ellis Investment Partners, LLC with notifications on news.